TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36458325
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (V14)
Study: 36458325
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (E14)
Study: 34338146
Drug: CUL4B siRNA
Normalized name: Sirna-027
DrugBank: Sirna-027 (DB05896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUL4B siRNA plus miR‐101‐3p inhibitor group
Study: 34817421
Drug: Noradrenaline 5
Normalized name: NORADRENALINE, (+/-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline 5 μg min-1
Study: 34817421
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg min-1
Study: 34237154
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus lenvatinib (12 mg orally once daily for body weight ≥60 kg or 8 mg for body weight <60 kg)
Study: 34237154
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus sorafenib (400 mg orally twice daily in 28-day cycles)
Study: 37432736
Drug: Low-dose ATG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATG
Study: 34443994
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy applied during sleep
Study: 34443994
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy applied in awake state
Study: 34443994
Drug: Live music
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live music therapy (general)
Study: 33051228
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg ×2 daily for 7 days followed by vaginal Lactobacillus crispatus CTV‐05 until clinical pregnancy scan week 7‐9
Study: 33051228
Drug: Clindamycin and
Normalized name: clindamycin and benzoyl peroxide KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin and placebo L. crispatus CTV‐05
Study: 34633260
Drug: S086 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: S086 (single ascending doses: 60-1080 mg)
Study: 34633260
Drug: S086 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: S086 (multiple ascending doses: 180-720 mg)
Study: 33167705
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy
Study: 35649167
Drug: Dextromethorphan-bupropion (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan-bupropion (45 mg-105 mg tablet), orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Study: 35649167
Drug: Placebo, orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Study: 34500216
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with two treatments
Study: 34500216
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with four treatments
Study: 34988703
Drug: Primary/interval debulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri‐weekly doses of paclitaxel + carboplatin
Study: 33530190
Drug: Sling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling treatment
Study: 34496848
Drug: Continuous boosted
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous boosted darunavir plus 2 nucleoside/nucleotide reverse‐transcriptase inhibitors (3DR)
Study: 36128262
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Olanzapine
Study: 32557475
Drug: Standard bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bowel preparation protocol (Control)
Study: 32557475
Drug: Standard bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bowel preparation protocol (Control, Per-protocol analysis)
Study: 36223406
Drug: 8 wk
Normalized name: Rheumatrex Dose Pack 12, 4 Wk Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 wk pulmonary rehabilitation (PR) + routine medication
Study: 36223406
Drug: Routine medication
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medication (Control Group)
Study: 34049519
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily from 2 days pre-operation to 14 days post-surgery
Study: 32259902
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (GDMT) for systolic heart failure, including renin angiotensin aldosterone system inhibitors, initiated at low doses with close monitoring of kidney function.
Study: 32306296
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (EQW)
Study: 33484485
Drug: Microwave ablation
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave ablation (MWA) followed by drug therapy
Study: 35271241
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug therapy only)
Study: 32519221
Drug: Additional adhesive
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional adhesive patches (RockaDex, New Zealand)
Study: 32519221
Drug: Adhesive patch
Normalized name: ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch use
Study: 32519221
Drug: Adhesive patch
Normalized name: ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch non-use
Study: 33030742
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (10 µg/day)
Study: 32600295
Drug: Immediately sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately sequential bilateral cataract surgery (ISBCS)
Study: 32600295
Drug: Delayed sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed sequential bilateral cataract surgery (DSBCS)
Study: 36235746
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg D-Pinitol (n = 10)
Study: 36235746
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg D-Pinitol (n = 6)
Study: 36235746
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg D-Pinitol from carob pods-derived syrup (n = 9)
Study: 36235746
Drug: D-Pinitol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Pinitol (various doses)
Study: 33960064
Drug: Daily or
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily or occasional physical activity (AOR = 0.35; AOR = 0.50)
Study: 37288499
Drug: Active photobiomodulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active photobiomodulation (PBM) therapy, 808 nm, 15 min, 16.5 J/cm2, self-applied at home for 3 months
Study: 37288499
Drug: Sham photobiomodulation
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham photobiomodulation therapy, self-applied at home for 3 months
Study: 34859632
Drug: Non-prophylactic antibiotics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prophylactic antibiotics
Study: 33789311
Drug: Pycnogenol® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol® (2 × 50 mg/day for a total of 12 weeks)
Study: 32325914
Drug: ANS-LD (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANS-LD (15 mg.kg−1.bw−1)
Study: 32325914
Drug: ANS-HD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANS-HD (30 mg.kg−1.bw−1)
Study: 34863330
Drug: Oral lyophilised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lyophilised FMT for 8 weeks
Study: 36378093
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation exercises (PREs) performed once a day for 4 weeks in addition to standard treatment
Study: 34855690
Drug: Alpha-2 agonists
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-2 agonists
Study: 35103237
Drug: Ultrasound-guided ACB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided ACB with 14 ml 0.25% levobupivacaine and 100 mcg clonidine
Study: 34167279
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ASL and TOF MRA
Study: 35138259
Drug: Unguided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided internet-based cognitive behavioral therapy (ICBT) for 4 weeks
Study: 33801969
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + virtual reality
Study: 34112520
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release 150 mg twice daily
Study: 34112520
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 21 mg once daily
Study: 33135436
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of 20 mg dexamethasone and a postoperative saline injection (Group B)
Study: 33135436
Drug: Two perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two perioperative doses of 10 mg dexamethasone (Group C)
Study: 33135436
Drug: Two perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two perioperative saline injections (Group A, placebo)
Study: 35656469
Drug: Persian medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persian medicine diet combined with Western medicine-based diet
Study: 35656469
Drug: Western medicine-based
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine-based diet
Study: 34702015
Drug: 2nd to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd to 5th place ensemble solutions
Study: 39287491
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy
Study: 34919862
Drug: Universal HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal HIV testing and treatment (annual HIV and multidisease testing, universal ART eligibility, patient-centred care)
Study: 32434067
Drug: Peanut Oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Oral Immunotherapy (OIT)
Study: 36827018
Drug: Selenium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium treatment
Study: 33874981
Drug: Intravenous Prolastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight for 4 weeks
Study: 33874981
Drug: Intravenous Prolastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight (single dose) followed by 0.9% sodium chloride for 3 weeks
Study: 33874981
Drug: Intravenous Prolastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin)
Study: 35551299
Drug: Vistusertib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vistusertib (125 mg twice daily for 2 days per week) + Anastrozole (1 mg daily)
Study: 33420936
Drug: Implementation fidelity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation fidelity and treatment acceptability
Study: 32396257
Drug: Ropinirole patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole patch (up to 64 mg/d)
Study: 32396257
Drug: Ropinirole extended-release
Normalized name: Ropinirole Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole extended-release tablet (up to 16 mg/d)
Study: 32783351
Drug: Canakinumab 2
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 2 mg/kg every 4 weeks (arm 1)
Study: 32783351
Drug: Canakinumab 4
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 4 mg/kg every 8 weeks (arm 2)
Study: 33855222
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg once daily (qd) for 24 weeks
Study: 33855222
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg qd at Week 12
Study: 37202447
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets
Study: 34864802
Drug: Half-dose photodynamic
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose photodynamic therapy (61 patients)
Study: 34864802
Drug: High-density subthreshold
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density subthreshold micropulse laser treatment (62 patients)
Study: 35927676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus standard of care (SOC)
Study: 35927676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus SOC
Study: 35381407
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of nadroparin 3800 IU over 4 hours
Study: 35381407
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of nadroparin
Study: 35381407
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration
Study: 35381407
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration
Study: 35887855
Drug: BoNT injections
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT injections alone
Study: 35887855
Drug: BoNT injections
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT injections with OA therapy
Study: 33648546
Drug: EPA and
Normalized name: Norwegian Cod Liver Oil With EPA and DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA and DHA (600 mg EPA and 260 mg DHA per day)
Study: 33847344
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g cod fillet twice weekly for 16 weeks
Study: 33417682
Drug: Canakinumab (anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (anti-inflammatory therapy)
Study: 33851734
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and acceptance-based treatment (MABT)
Study: 36179950
Drug: Oral factor
Normalized name: intrinsic factor Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral factor Xa inhibitors (apixaban, betrixaban, rivaroxaban)
Study: 32965585
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg twice daily
Study: 36179950
Drug: Oral factor
Normalized name: intrinsic factor Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral factor Xa inhibitors
Study: 34283917
Drug: Multicomponent psychological
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent psychological intervention administered through an interactive multimedia online videogame with a complementary smartphone app
Study: 33085033
Drug: JNJ‐55920839 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐55920839 10 mg/kg IV 6 times biweekly in subjects with SLE
Study: 33085033
Drug: JNJ‐55920839 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐55920839 (various doses between 0.3 and 15 mg/kg IV or 1 mg/kg SC) in healthy subjects
Study: 33085033
Drug: JNJ‐55920839 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐55920839 (10 mg/kg IV) in subjects with SLE
Study: 33085033
Drug: JNJ‐55920839 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐55920839 (various doses) in healthy subjects
Study: 34849546
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU/d) with baseline 25(OH)D <20 ng/mL
Study: 34849546
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (2000 IU/d) with baseline 25(OH)D of 20-30 ng/mL
Study: 36283748
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care treatment
Study: 34334720
Drug: CHO hydrogel
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO hydrogel (90 g·h‐1 of 2:1 glucose‐fructose)
Study: 34334720
Drug: Standard CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CHO solution (nonhydrogel)
Study: 34139464
Drug: modified lower-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified lower-protein (mLP) infant formula (1.7 g protein/100 kcal)
Study: 34139464
Drug: control formula
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: control formula (CTRL) (2.1 g protein/100 kcal)
Study: 35481442
Drug: Gabapentin 20
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 20 mg/kg
Study: 35733283
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (500 mg)
Study: 32424868
Drug: Split high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split high-dose sennoside solutions (1000 mg)
Study: 32424868
Drug: Split-dose polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose polyethylene glycol (4 L)
Study: 35102477
Drug: Mini-implant assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implant assisted rapid palatal expansion (MARPE)
Study: 36883362
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: 35986649
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplements (ONSs) (400 kcal/day) and family-centered nutrition education (once every 2 weeks)
Study: 35986649
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplements (ONSs) and family-centered nutrition education
Study: 34472598
Drug: Slow breathing
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow breathing exercise (SBE) performed at home, 30 minutes daily for 12 weeks
Study: 39260927
Drug: Evogliptin 5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 5 mg
Study: 33956209
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic usage > 40 mg furosemide-equivalent dose
Study: 33956209
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic usage 1-40 mg furosemide-equivalent dose
Study: 33956209
Drug: No baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: No baseline loop diuretic usage
Study: 35451469
Drug: Magnesium (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (3.2 g daily for 72 hours preoperatively and 1.6 g on the day of surgery)
Study: 34081085
Drug: Risk-reducing salpingo-oophorectomy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risk-reducing salpingo-oophorectomy (RRSO) without hormone replacement therapy
Study: 34081085
Drug: Risk-reducing salpingo-oophorectomy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risk-reducing salpingo-oophorectomy (RRSO) with hormone replacement therapy
Study: 32522273
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose Lingguizhugan decoction (SLGD)
Study: 32522273
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Lingguizhugan decoction (LLGD)
Study: 34693689
Drug: Recognan (citicoline),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recognan (citicoline), 500 mg daily for 30 days
Study: 32784231
Drug: Low-dose lidocaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lidocaine (CIESI-L)
Study: 32903044
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy
Study: 35223106
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (TXA)
Study: 33978745
Drug: Zoledronate infusion
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate infusion after denosumab treatment (≤ 6 Group)